Table 1.
Overview of NAI mAbs and their epitopes.
| Epitope | Mechanism of action | Neuraminidase inhibition? | mAb | |
|---|---|---|---|---|
| (reference) | ||||
| * structural data available Bold: mentioned in text | ||||
| Small substrate assay | Large substrate assay | |||
| The catalytic site and its rim | (partially) block access to catalytic site | Yes | Yes | NA-73* (98, 99) |
| NA-108 (98, 99) | ||||
| HCA-2 (100, 101) | ||||
| IG05 (102) | ||||
| 2E01 (102) | ||||
| HF5 (103, 104) | ||||
| 3G1 (52) | ||||
| 229-1 F06 (50) | ||||
| 229-1G03 (50) | ||||
| 229-11)05 (50) | ||||
| CDR3 loop insertion in catalytic site | Yes | Yes | IG01* (105) | |
| IG04* (105) | ||||
| IE01* (105) | ||||
| Z2B3* (106, 107) | ||||
| NA-45* (98, 99) | ||||
| bind loop surrounding the cavity of the catalytic site | Yes | Yes | Mem5* (108) | |
| NC10* (109) | ||||
| NC41* (110) | ||||
| IG8* (111) | ||||
| 229-1D05 (50, 112) | ||||
| 229-1C02 (50, 112) | ||||
| Outside of the catalytic site | bind linear epitope on tip | No | Yes | NA-63* (98, 99) |
| NA-80* (98, 99) | ||||
| unknown | No | Yes | IF2 (52) | |
| N1-C4 (113) | ||||
| bind interface between adjacent monomers causing steric hindrance | No | Yes | CD6* (103) | |
| N8-4 (114) | ||||
| 4F11 (52) | ||||
| NA-22* (98, 99) | ||||
Neuraminidase inhibition activity is determined via small substrate (MUNANA or NA-STAR) and large substrate (ELLA) assays. mAbs in bold are mentioned in the text, while other mAbs are referenced for completeness.